|Bid||79.77 x 1400|
|Ask||80.80 x 900|
|Day's Range||79.27 - 80.13|
|52 Week Range||52.83 - 80.19|
|Beta (3Y Monthly)||0.38|
|PE Ratio (TTM)||34.40|
|Earnings Date||Apr 30, 2019|
|Forward Dividend & Yield||2.20 (2.79%)|
|1y Target Est||82.81|
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Today I will be providing a simple run through ofRead More...
Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday. Nearly 90 percent of patients who received the combination therapy were still alive after 12 months compared with about 78 percent of patients who were alive after a year when treated with the older drug Sutent, data showed. Merck on Monday released interim data from the trial, saying the combination reduced the risk of death by 47 percent compared with Sutent.
Results from Phase 3 KEYNOTE-426 Study Presented Today at the 2019 Genitourinary Cancers Symposium and Published in the New England Journal of Medicine Also Showed Risk o
Announcement: Moody's announces completion of a periodic review of ratings of Merck & Co., Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Merck & Co., Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Growth driversOn its fourth-quarter earnings conference call, Merck & Co. (MRK) highlighted its oncology, vaccines, hospital and specialty care, and animal
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Dividend projectionsMerck & Co. (MRK) and GlaxoSmithKline (GSK) reported dividends per share of $1.99 and $2.08, respectively, in 2018.Analysts expect
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Expenses guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for a low- to mid-single-digit YoY (year-over-year) rise
Application Based on Overall Survival and Progression-Free Survival Data from Phase 3 KEYNOTE-426 Trial
Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and orphan diseases in pediatrics and neurology, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,202,363 ("the ‘363 patent") on Feb. 12, 2019, which is directed to CERC‑301, an oral, NR2B-specific, NMDA receptor antagonist. CERC-301 is a selective NR2B-specific NMDA receptor antagonist with a unique mechanism of action tested in 375 subjects to date. CERC-301 is being developed for the treatment of Neurogenic Orthostatic Hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy and Pure Autonomic Failure.
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)EPS guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for non-GAAP (generally accepted accounting principles) EPS
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Revenue guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for revenue of $43.2 billion–$44.7 billion, a YoY
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?Share price movements On February 11, Merck & Co. (MRK) closed at $76.71, 1.04% lower than its previous closing price, 45.20% higher than its 52-week low of $52.83, and 4.34% lower
Merck & Co Inc said on Thursday it was launching three late-stage studies for its cancer immunotherapy Keytruda as a combination treatment for prostate cancer after the drug showed anti-tumor activity ...
AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
Cyber Daily: Bumpy Road to NotPetya Insurance Payouts; Espionage in Iran Cyber Daily: Bumpy Road to NotPetya Insurance Payouts; Espionage in Iran By Kim S. Nash Good day. Is physical damage caused by cyber incidents covered by property insurance? Is data property? Who determines when a cyberattack is an act of war? And how? In lawsuits against their insurance firms, pharmaceutical firm Merck & Co.
Research Program Expanded Based on Promising Data Shown with KEYTRUDA® in Combination with LYNPARZA® , Chemotherapy and Anti-Hormone Agents in Patients wi
AstraZeneca shares traded sharply higher Thursday after the U.K.-based drugmaker posted stronger-than-forecast fourth quarter earnings, and said 2019 revenues would continue to rise, thanks to increasing ...
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.
Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Aduro (ADRO) doses the first patient in a phase I study on ADU-S100 in combination with Yervoy for the treatment of relapsed and refractory melanoma. Shares rise.